hip and knee osteoarthritis
Conditions
Interventions
Manual TKA:None
Robot-Assisted TKA:None
Manual THA:None
Robot-Assisted THA:None
Sponsors
The Fourth Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who underwent primary unilateral THA or TKA performed by Chief Surgeon Xu Chi (between January 2023 and June 2025); 2. Aged 18-80 years, meeting the ACR diagnostic criteria for osteoarthritis; 3. Absence of severe postoperative surgical complications; 4. Provision of signed informed consent and commitment to complete follow-up assessments.hnique.
Exclusion criteria
Exclusion criteria: 1. Patients with other severe diseases affecting hip or knee joint symptoms and function, such as hemiplegia, Parkinson's disease, bone tumors, etc.; 2. Patients with severe heart disease, arrhythmia, hypertension, frail elderly patients in poor general condition, or those with severe internal medical diseases such as dysfunction of vital organs (heart, lungs, liver, kidneys) or tumors; 3. Patients with any condition or circumstance which, in the evaluator's judgment, may pose a significant risk to the patient, potentially confound the study results, or severely interfere with the patient's participation in the study; 4. Patients who are physically or mentally unhealthy, unable to cooperate with the trial, or cannot provide written voluntary informed consent for participation in the clinical research; 5. Female subjects who are pregnant or breastfeeding; 6. Subjects with amputation above the knee on the contralateral or ipsilateral lower limb; 7. Subjects with active infection; 8. Subjects with diseases or unhealthy conditions deemed by the investigator likely to affect their participation in this study, such as malignant diseases, serious illnesses, alcohol or drug addiction, and/or mental disorders; 9. Subjects with severe neurological or musculoskeletal diseases that may affect gait or weight-bearing (e.g., muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, Charcot arthropathy); 10. Subjects who cannot articulate, read, and understand the questions in the subjective questionnaires specified in the study protocol and cannot provide feedback in the appropriate language; 11. Subjects with other diseases and a life expectancy of less than 2 years; 12. Subjects with concurrent diseases that restrict their participation in the study, prevent compliance with follow-up, or compromise the scientific integrity of the study; 13. Subjects currently participating in another drug or device clinical trial; 14. Subjects who are currently incarcerated; 15. Subjects with known allergy to any component of the implant (e.g., metal); 16. Patients deemed unsuitable for inclusion in this study by the chief surgeon.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Net Promoter Score,NPS;Enhanced Recovery After Surgery (ERAS) Scoring System; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale (VAS) pain score;Forgotten Joint Score-12 (FJS-12);Patient Perception; | — |
Countries
China
Contacts
Public ContactChai Wei
Chinese PLA General Hospital
Outcome results
None listed